AXL in myeloid malignancies – an elusive target?
2024

AXL in Myeloid Malignancies

Sample size: 25 publication Evidence: moderate

Author Information

Author(s): Pia Aehnlich, Katharina Leuchte, Claudia Schöllkopf, Sara Fresnillo Salo, Tina J. Seremet, Estrid Høgdall, Özcan Met, Kirsten Grønbaek, Per Thor Straten

Primary Institution: Copenhagen University Hospital

Hypothesis

Does AXL expression in myeloid neoplasms affect the efficacy of AXL inhibitors?

Conclusion

The study found unexpectedly low AXL expression in bone marrow myeloblasts from patients with myeloid neoplasms.

Supporting Evidence

  • AXL expression was generally absent or very low in AML myeloblasts.
  • AXL was undetectable in 20 out of 25 patients.
  • Previous studies linked AXL overexpression to poor prognosis in AML.

Takeaway

This study looked at a protein called AXL in blood cancer cells and found that it was mostly missing, which means treatments targeting AXL might work differently than expected.

Methodology

The study assessed AXL expression in AML cell lines and bone marrow myeloblasts using flow cytometry.

Limitations

The study only included a small number of patients and focused on specific cancer types.

Participant Demographics

All patients were above 18 years of age, with 22 having AML, 2 CML in blast crisis, and 1 CMML transformed into AML.

Digital Object Identifier (DOI)

10.1186/s40364-024-00704-8

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication